NYSE$WELL
Welltower Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Welltower's Q3 2022 performance reflected growth in normalized FFO and same-store NOI, driven by strong performance in the Seniors Housing Operating portfolio. Strategic investments and capital management activities were undertaken to enhance the company's financial position and growth prospects.
Welltower reported a net loss of $0.01 per diluted share, but normalized FFO of $0.84 per diluted share. The company saw same-store NOI growth of 7.2%, driven by a 17.6% increase in the Seniors Housing Operating portfolio. Welltower completed $1.1 billion in pro rata gross investments and reduced variable rate debt by $817 million after the quarter ended.
- Net loss attributable to common stockholders was $0.01 per diluted share; normalized FFO was $0.84 per diluted share.
- Normalized FFO growth attributable to common stockholders per diluted share increased by 5.0% year-over-year (6.2% on a constant currency basis, excluding Provider Relief Funds).
- Total portfolio same-store NOI grew by 7.2%, with Seniors Housing Operating portfolio same-store NOI growing by 17.6%.
- Completed $1.1 billion of pro rata gross investments, including $850 million in acquisitions and loan funding, and $203 million in development funding.
Headline financials
Revenue & EPS history
Welltower · Revenue · Quarterly
$1.47B
Revenue by segment
Welltower · $1.07B total across 1 segment · Q3 2022
- Resident fees and services$1.07B+27.9%100.0%
Forward guidance
Welltower expects net income attributable to common stockholders to be in the range of $0.08 to $0.13 per diluted share and normalized FFO attributable to common stockholders to be in the range of $0.80 to $0.85 per diluted share for the quarter ending December 31, 2022.
Tailwinds
- Average blended SSNOI growth of 8.5% to 10.5% expected.
- Seniors Housing Operating SSNOI growth of approximately 18.5% to 23.5% expected.
- Seniors Housing Triple-net SSNOI growth of approximately 5% to 6% expected.
- Outpatient Medical SSNOI growth of approximately 1.5% to 2.5% expected.
- Health System SSNOI growth of approximately 2.75% expected.
Headwinds
- Fourth quarter guidance does not include the recognition of any Provider Relief Funds.
- Increased interest rates on floating rate debt and a strengthening U.S. Dollar are expected to reduce fourth quarter 2022 normalized FFO by approximately $0.03 per diluted share versus the third quarter 2022.
- Increased interest rates on floating rate debt and a strengthening U.S. Dollar are expected to reduce fourth quarter 2022 normalized FFO by approximately $0.06 per diluted share versus the fourth quarter 2021.
- General and administrative expenses are anticipated to be approximately $34 million to $36 million.
- Stock-based compensation expense is anticipated to be approximately $6 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.7%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+3.0%
Avg return
30 days after
61%
43 / 70 earnings
Positive
+9.1%
Q3 2022
Best reaction
-12.9%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | +1.4% | -3.9% | |
| Q4 2025 | +3.5% | +4.9% | +3.5% | |
| Q3 2025 | -1.6% | -0.9% | +12.9% | |
| Q2 2025 | +0.6% | +2.5% | +4.5% | |
| Q1 2025 | +1.6% | +1.1% | +2.7% | |
| Q4 2024 | +2.2% | +4.6% | +3.1% | |
| Q3 2024 | +5.5% | +2.4% | +7.0% | |
| Q2 2024 | +2.2% | +2.7% | +10.3% | |
| Q1 2024 | +1.0% | +1.6% | +6.7% | |
| Q4 2023 | +6.6% | +6.4% | +4.7% | |
| Q3 2023 | +2.8% | +8.7% | +8.4% | |
| Q2 2023 | +4.4% | +1.7% | +2.3% | |
| Q1 2023 | -0.9% | +0.6% | -4.7% | |
| Q4 2022 | +3.0% | +2.2% | -9.2% | |
| Q3 2022 | +9.1% | +17.4% | +6.6% | |
| Q2 2022 | +2.1% | +1.3% | -6.4% | |
| Q1 2022 | -0.1% | +1.5% | -4.4% | |
| Q4 2021 | +5.3% | +4.0% | +15.5% | |
| Q3 2021 | +2.1% | +3.1% | -2.9% | |
| Q2 2021 | -0.6% | -0.3% | -2.0% | |
| Q1 2021 | -0.5% | +0.0% | -2.2% | |
| Q4 2020 | +2.7% | +6.8% | +16.1% | |
| Q3 2020 | +1.1% | +5.0% | +19.5% | |
| Q2 2020 | +5.9% | +7.8% | +14.7% | |
| Q1 2020 | -12.9% | -12.7% | +27.8% | |
| Q4 2019 | +3.3% | +5.2% | -39.6% | |
| Q3 2019 | +1.7% | +2.4% | -2.4% | |
| Q2 2019 | -0.3% | +1.1% | +6.7% | |
| Q1 2019 | +2.6% | +4.7% | +10.6% | |
| Q4 2018 | +0.2% | +0.2% | +0.6% | |
| Q3 2018 | +0.1% | -0.2% | +8.3% | |
| Q2 2018 | -4.1% | -2.1% | +2.5% | |
| Q1 2018 | +4.7% | +8.6% | +12.6% | |
| Q4 2017 | +0.8% | -3.3% | -3.6% | |
| Q3 2017 | +1.1% | +0.2% | -2.7% | |
| Q2 2017 | +0.8% | -0.5% | -1.2% | |
| Q1 2017 | -0.2% | +0.2% | +5.6% | |
| Q4 2016 | +2.9% | +4.6% | +4.1% | |
| Q3 2016 | -2.1% | -1.7% | -6.9% | |
| Q2 2016 | -2.7% | -4.1% | -4.0% | |
| Q1 2016 | +5.8% | — | — | |
| Q4 2015 | +4.7% | — | — | |
| Q3 2015 | -1.6% | — | — | |
| Q2 2015 | -1.8% | — | — | |
| Q1 2015 | -1.0% | — | — | |
| Q4 2014 | +3.2% | — | — | |
| Q3 2014 | +0.4% | — | — | |
| Q2 2014 | +1.7% | — | — | |
| Q1 2014 | +1.2% | — | — | |
| Q4 2013 | -0.7% | — | — | |
| Q3 2013 | -2.8% | — | — | |
| Q2 2013 | -0.9% | — | — | |
| Q1 2013 | -1.3% | — | — | |
| Q4 2012 | -2.0% | — | — | |
| Q3 2012 | +1.5% | — | — | |
| Q2 2012 | -3.3% | — | — | |
| Q1 2012 | -1.2% | — | — | |
| Q4 2011 | -2.6% | — | — | |
| Q3 2011 | -4.3% | — | — | |
| Q2 2011 | +5.6% | — | — | |
| Q1 2010 | +0.2% | — | — | |
| Q1 2011 | -0.2% | — | — | |
| Q4 2009 | +1.7% | — | — | |
| Q4 2010 | +1.7% | — | — | |
| Q1 2009 | +1.7% | — | — | |
| Q4 2008 | +1.7% | — | — | |
| Q3 2009 | -4.4% | — | — | |
| Q3 2010 | -4.4% | — | — | |
| Q2 2010 | +0.2% | — | — | |
| Q2 2009 | +0.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro